URGN Q1 2024 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+9.2% YoY

Gross Profit

$17M90.8% margin

Operating Income

-$26M-137.1% margin

Net Income

-$32M-171.9% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

-20.2%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$201M

Total Liabilities

$241M

Stockholders' Equity

-$40M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$17M	+9.2%
Gross Profit	$17M	$15M	+14.2%
Operating Income	-$26M	-$22M	-16.8%
Net Income	-$32M	-$30M	-6.9%

Revenue Segments

Jelmyto

$19M100%